OTCMKTS:RCDTF Recordati Industria Chimica E Farmaceutica (RCDTF) Stock Price, News & Analysis $65.44 0.00 (0.00%) As of 07/1/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestBuy This Stock About Recordati Industria Chimica E Farmaceutica Stock (OTCMKTS:RCDTF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get RCDTF alerts:Sign Up Key Stats Today's Range$65.44▼$65.4450-Day Range$56.04▼$65.4452-Week Range$49.00▼$65.44VolumeN/AAverage Volume15 shsMarket CapitalizationN/AP/E Ratio32.72Dividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. The company also develops CARBAGLU for hyperammonemia due to NAGS deficiency; QARZIBA, an apeiron for the treatment of high-risk neuroblastoma patients with a partial response at the chemotherapeutical through myeloablative therapy and stem cell transplantation, and relapsed or refractory neuroblastoma. In addition, it offers SYLVANT for the treatment of idiopathic multicentric Castleman diseases; REAGILA for Schizophrenia; and ELIGARD for hormone-dependent prostate cancer, as well as CAPHOSOL, a medical device for treatment of oral mucositis due to chemo and radiation therapy. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L. Read More Receive RCDTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recordati Industria Chimica E Farmaceutica and its competitors with MarketBeat's FREE daily newsletter. Email Address RCDTF Stock News HeadlinesContrasting Recordati Industria Chimica E Farmaceutica (RCDTF) & The CompetitionJune 24, 2025 | americanbankingnews.comDrug maker Recordati's Q1 revenue rises 11.9%, confirms 2025 guidanceMay 9, 2025 | msn.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.July 2 at 2:00 AM | Paradigm Press (Ad)Recordati stock rises following 1Q earnings beatMay 8, 2025 | investing.comRecordati, la cassa balza a 158 milioni e il debito cala a 2 miliardiMay 8, 2025 | msn.comRecordati Industria Chimica e Farmaceutica SPA (0KBS) Receives a Hold from RBC CapitalApril 26, 2025 | markets.businessinsider.comRecordati, la Fda amplia l’uso del farmaco Isturisa. Ma il titolo cade in borsa, ecco perchéApril 18, 2025 | msn.com3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%April 17, 2025 | finance.yahoo.comSee More Headlines RCDTF Stock Analysis - Frequently Asked Questions How have RCDTF shares performed this year? Recordati Industria Chimica E Farmaceutica's stock was trading at $55.54 at the beginning of 2025. Since then, RCDTF shares have increased by 17.8% and is now trading at $65.44. View the best growth stocks for 2025 here. How do I buy shares of Recordati Industria Chimica E Farmaceutica? Shares of RCDTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today7/02/2025Next Earnings (Estimated)7/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolOTCMKTS:RCDTF Previous SymbolNASDAQ:RCDTF CIKN/A Webwww.recordati.com Phone390-248-7871Fax39-02-4007-3747Employees4,583Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio32.72 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio1.16 Current Ratio1.61 Quick Ratio1.06 Sales & Book Value Annual Sales$2.53 billion Price / SalesN/A Cash Flow$3.06 per share Price / Cash Flow21.39 Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta0.21 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (OTCMKTS:RCDTF) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recordati Industria Chimica E Farmaceutica S.P.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recordati Industria Chimica E Farmaceutica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.